Compare COKE & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COKE | ABVX |
|---|---|---|
| Founded | 1902 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 9.6B |
| IPO Year | N/A | N/A |
| Metric | COKE | ABVX |
|---|---|---|
| Price | $165.94 | $123.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $112.83 |
| AVG Volume (30 Days) | 463.7K | ★ 1.7M |
| Earning Date | 10-29-2025 | 08-11-2025 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | ★ 22.14 | N/A |
| EPS | ★ 7.03 | N/A |
| Revenue | ★ $7,070,308,000.00 | $7,073,400.00 |
| Revenue This Year | N/A | $6.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.59 | ★ N/A |
| Revenue Growth | ★ 4.22 | N/A |
| 52 Week Low | $105.21 | $4.77 |
| 52 Week High | $168.21 | $138.49 |
| Indicator | COKE | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 67.36 | 59.90 |
| Support Level | $159.13 | $107.06 |
| Resistance Level | $168.21 | $138.49 |
| Average True Range (ATR) | 3.73 | 7.15 |
| MACD | -1.32 | 0.19 |
| Stochastic Oscillator | 70.70 | 58.28 |
Coca-Cola Consolidated Inc distributes, markets and manufactures nonalcoholic beverages. It offer a range of nonalcoholic beverage products and flavors, including both sparkling and still beverages. Sparkling beverages are carbonated beverages and the Company's principal sparkling beverage is Coca Cola. Still beverages include energy products and noncarbonated beverages such as bottled water, ready-to-drink tea, ready-to-drink coffee, enhanced water, juices and sports drinks. The Company has three operating segments: Nonalcoholic Beverages, All Other and Eliminations. key revenue is generated from Nonalcoholic Beverages.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.